JPH0343252B2 - - Google Patents
Info
- Publication number
- JPH0343252B2 JPH0343252B2 JP56167997A JP16799781A JPH0343252B2 JP H0343252 B2 JPH0343252 B2 JP H0343252B2 JP 56167997 A JP56167997 A JP 56167997A JP 16799781 A JP16799781 A JP 16799781A JP H0343252 B2 JPH0343252 B2 JP H0343252B2
- Authority
- JP
- Japan
- Prior art keywords
- surfactant
- fatty alcohol
- surfactant composition
- pulmonary surfactant
- mammalian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 239000003580 lung surfactant Substances 0.000 claims abstract description 47
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims abstract description 32
- 150000002191 fatty alcohols Chemical class 0.000 claims abstract description 29
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940066294 lung surfactant Drugs 0.000 claims abstract description 5
- 239000008777 Glycerylphosphorylcholine Substances 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 4
- 229960004956 glycerylphosphorylcholine Drugs 0.000 claims abstract description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 17
- 239000000725 suspension Substances 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims 1
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 abstract description 64
- 210000004072 lung Anatomy 0.000 abstract description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 239000000463 material Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 230000035800 maturation Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000010408 film Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- -1 unsaturated phosphatidyl glycols Chemical class 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001030 gas--liquid chromatography Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 230000004202 respiratory function Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- XCXKZBWAKKPFCJ-UHFFFAOYSA-N Hexadecan-2-one Chemical compound CCCCCCCCCCCCCCC(C)=O XCXKZBWAKKPFCJ-UHFFFAOYSA-N 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000002327 glycerophospholipids Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- VOJREVRIHQPQTJ-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCO VOJREVRIHQPQTJ-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/200,216 US4312860A (en) | 1980-10-24 | 1980-10-24 | Lung surfactant compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5799524A JPS5799524A (en) | 1982-06-21 |
| JPH0343252B2 true JPH0343252B2 (enExample) | 1991-07-01 |
Family
ID=22740789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56167997A Granted JPS5799524A (en) | 1980-10-24 | 1981-10-22 | Mammal lung surface active drug composition |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4312860A (enExample) |
| EP (1) | EP0050793B1 (enExample) |
| JP (1) | JPS5799524A (enExample) |
| AT (1) | ATE7853T1 (enExample) |
| BG (1) | BG60737B2 (enExample) |
| CA (1) | CA1184503A (enExample) |
| CS (1) | CS384991A3 (enExample) |
| DE (2) | DE19375071I2 (enExample) |
| NL (1) | NL930059I2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3229179C2 (de) * | 1982-08-05 | 1986-04-17 | A. Nattermann & Cie GmbH, 5000 Köln | Lungensurfactant |
| JPS59164724A (ja) * | 1983-03-10 | 1984-09-17 | Tokyo Tanabe Co Ltd | サ−フアクタント及びそれを含有する呼吸窮迫症候群治療剤 |
| US4933280A (en) * | 1984-12-11 | 1990-06-12 | California Biotechnology Inc. | Recombinant DNA sequence encoding Alveolar Surfactant Protein |
| US5840527A (en) * | 1984-12-11 | 1998-11-24 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Recombinant alveolar surfactant protein |
| US4659805A (en) * | 1984-12-11 | 1987-04-21 | California Biotechnology, Inc. | Recombinant alveolar surfactant protein |
| US5169761A (en) * | 1984-12-11 | 1992-12-08 | California Biotechnology Inc. | Dna encoding and expression systems for alveolar surfactant proteins |
| ATE78158T1 (de) * | 1985-05-22 | 1992-08-15 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
| US5110806A (en) * | 1985-06-26 | 1992-05-05 | The Regents Of The University Of California | Lung surfactant compositions |
| US4826821A (en) * | 1985-06-26 | 1989-05-02 | The Regents Of The University Of California | Lung surfactant compositions |
| FR2586587B1 (fr) * | 1985-08-30 | 1987-10-23 | Adir | Nouveaux surfactants artificiels, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| US4812314A (en) * | 1986-02-24 | 1989-03-14 | Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization | Lipid replacement therapy |
| US5013720A (en) * | 1986-05-06 | 1991-05-07 | Abbott Laboratories | SAP-6-Val proteins and methods |
| US5032585A (en) * | 1987-02-17 | 1991-07-16 | Board Of Regents, The University Of Texas System | Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy |
| IT1203873B (it) * | 1987-04-08 | 1989-02-23 | Chiesi Farma Spa | Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e |
| US4861756A (en) * | 1988-03-08 | 1989-08-29 | Merrell Dow Pharmaceuticals Inc. | Synthetic pulmonary surfactant |
| US5207220A (en) * | 1989-12-12 | 1993-05-04 | Burroughs Wellcome Co. | Method for administering pharmaceuticals, including liquid surfactant, to the lungs |
| US5614216A (en) * | 1990-10-17 | 1997-03-25 | The Liposome Company, Inc. | Synthetic lung surfactant |
| GB9120005D0 (en) * | 1991-09-19 | 1991-11-06 | Wellcome Found | Method of administering phospholipid dispersions |
| US6235308B1 (en) | 1994-06-10 | 2001-05-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of treating hypertension |
| US5622715A (en) * | 1994-06-10 | 1997-04-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of improving renal function |
| US5698537A (en) * | 1996-06-18 | 1997-12-16 | Clarion Pharmaceuticals Inc. | Method of lowering the viscosity of mucus |
| US5883084A (en) * | 1998-06-08 | 1999-03-16 | Clarion Pharmaceuticals Inc. | Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine |
| US6180142B1 (en) * | 1998-08-21 | 2001-01-30 | The Regents Of The University Of California | Reduction of surfactant inactivation in pulmonary surfactant therapy |
| US6576224B1 (en) * | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| US20020061281A1 (en) * | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| CN1429086A (zh) | 2000-03-13 | 2003-07-09 | 医疗物理有限公司 | 使用气态超极化129Xe的直接注射的诊断步骤以及相关系统和产品 |
| GB0026239D0 (en) * | 2000-10-26 | 2000-12-13 | Britannia Pharmaceuticals Ltd | Surface active lipids in treatment of wet lung |
| CA2564868C (en) * | 2004-04-28 | 2013-11-26 | Molecules For Health, Inc. | Methods for treating or preventing restenosis and other vascular proliferative disorders |
| JPWO2005105111A1 (ja) * | 2004-04-29 | 2008-07-31 | 相男 李 | 人工肺サーファクタント組成物およびその使用方法 |
| WO2009049159A1 (en) | 2007-10-10 | 2009-04-16 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
| WO2012170677A1 (en) | 2011-06-07 | 2012-12-13 | Parion Sciences, Inc. | Methods of treatment |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| KR102109223B1 (ko) | 2012-05-29 | 2020-05-11 | 패리온 사이언스 인코퍼레이티드 | 안구 건조 및 다른 점막 질환의 치료를 위한 나트륨 채널 차단제 활성을 보유하는 덴드리머 유사 아미노 아미드 |
| CA2896686A1 (en) | 2012-12-17 | 2014-06-26 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
| SG11201504799QA (en) | 2012-12-17 | 2015-07-30 | Parion Sciences Inc | Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration |
| EP2931712B8 (en) | 2012-12-17 | 2018-05-23 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
| US11219843B2 (en) * | 2019-07-08 | 2022-01-11 | Nik Paya Karen Pharmed | Extraction of animal-derived pulmonary surfactants |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE388023C (de) * | 1922-02-14 | 1924-01-07 | Chem Fab | Verfahren zur Herstellung von waesserigen Lezithinemulsionen |
| US3577446A (en) * | 1968-09-09 | 1971-05-04 | American Home Prod | Phosphatidylalkanolamine derivatives |
| DE2629135A1 (de) * | 1976-06-29 | 1978-01-12 | Nattermann A & Cie | Neue phospholipid-derivate von prostaglandinen und verfahren zu ihrer herstellung |
| DE2900300A1 (de) * | 1979-01-05 | 1980-07-17 | Lebrecht Von Dr Klitzing | Verfahren einer prophylaxe zur vermeidung des atemnotsyndroms bei fruehgeborenen und bei der schocklunge |
-
1980
- 1980-10-24 US US06/200,216 patent/US4312860A/en not_active Expired - Lifetime
-
1981
- 1981-10-14 EP EP81108298A patent/EP0050793B1/en not_active Expired
- 1981-10-14 DE DE19813164207 patent/DE19375071I2/de active Active
- 1981-10-14 AT AT81108298T patent/ATE7853T1/de active
- 1981-10-14 DE DE8181108298T patent/DE3164207D1/de not_active Expired
- 1981-10-22 JP JP56167997A patent/JPS5799524A/ja active Granted
- 1981-10-23 CA CA000388565A patent/CA1184503A/en not_active Expired
-
1991
- 1991-12-17 CS CS913849A patent/CS384991A3/cs unknown
-
1993
- 1993-06-11 NL NL930059C patent/NL930059I2/nl unknown
- 1993-08-26 BG BG098075A patent/BG60737B2/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL930059I1 (nl) | 1993-09-01 |
| ATE7853T1 (de) | 1984-06-15 |
| EP0050793B1 (en) | 1984-06-13 |
| DE3164207D1 (en) | 1984-07-19 |
| JPS5799524A (en) | 1982-06-21 |
| DE19375071I2 (de) | 2006-05-04 |
| US4312860A (en) | 1982-01-26 |
| EP0050793A1 (en) | 1982-05-05 |
| CS384991A3 (en) | 1992-10-14 |
| CA1184503A (en) | 1985-03-26 |
| BG60737B2 (bg) | 1996-01-31 |
| NL930059I2 (nl) | 1994-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0343252B2 (enExample) | ||
| US4826821A (en) | Lung surfactant compositions | |
| US5299566A (en) | Method of administering phospholipid dispersions | |
| HU211950A9 (en) | Natural pulmonary surfactant, method of preparation and pharmaceutical compositions | |
| JPS6296425A (ja) | 人工の、肺表面活性剤及びそれを含有する医薬組成物 | |
| US6770619B2 (en) | Lung surfactant compositions with dynamic swelling behavior | |
| US6129934A (en) | Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction | |
| JP2008525490A (ja) | 肺表面活性物質の配合物 | |
| US5110806A (en) | Lung surfactant compositions | |
| CN114159546B (zh) | 新一代合成肺表面活性物质制剂及其临床应用 | |
| CN102448498A (zh) | 包括肺表面活性物质和类固醇的治疗组合 | |
| EP2538960B1 (en) | Surfactant compositions comprising polypeptide complexes | |
| KR20190099422A (ko) | 발달하는 bpd의 치료를 위한 폐 계면활성제 및 스테로이드를 포함하는 치료 조합물 | |
| US20100317636A1 (en) | Reducing the risk of chronic lung disease in infants | |
| JP3376582B2 (ja) | 合成ペプチド、それを含有する肺サーファクタント及び呼吸窮迫症候群治療剤 | |
| KR101721309B1 (ko) | 계면활성 단백질 ｂ(ｓｐ－ｂ) 및 계면활성 단백질 ｃ(ｓｐ－ｃ)의 유사체를 포함하는 합성 폐 계면활성제 조성물 | |
| KR960013436B1 (ko) | 천연 폐 계면활성제, 그의 제조방법 및 이것을 함유하는 제약 조성물 | |
| KR101784651B1 (ko) | 계면활성 단백질 ｂ(ｓｐ－ｂ) 및 계면활성 단백질 ｃ(ｓｐ－ｃ)의 유사체를 포함하는 합성 폐 계면활성제 조성물 | |
| Park et al. | In vitro inhibition of biophysical surface properties and change in ultrastructures of exogenous pulmonary surfactant by albumin or fibrinogen | |
| JPS60237023A (ja) | 界面活性剤欠乏起因の呼吸困難症候群を治療するための薬剤およびその製造法 |